Conventional chemotherapeutic regimens for similar aggressive NHLs provide no specific cure for PEL, although several lines of work are currently underway to develop anti-PEL therapies such as pro-apoptotic agents bortezomib and azidothymidine, anti-proliferative antibiotic rapamycin, p53 activator nutlin-3a, anti-viral compounds cidofovir and interferon-α, and KSHV latency gene blocking agents glycyrrhizic acid (GA) and small RNA transcripts [1], [3]–[12]. The gene discussed is TP53; the disease is primary effusion lymphoma.